Details for Patent: 10,898,573
✉ Email this page to a colleague
Which drugs does patent 10,898,573 protect, and when does it expire?
Patent 10,898,573 protects UPNEEQ and is included in one NDA.
This patent has twenty-nine patent family members in seventeen countries.
Summary for Patent: 10,898,573
| Title: | Oxymetazoline compositions |
| Abstract: | The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage. |
| Inventor(s): | Tina deVries, David Jacobs |
| Assignee: | RVL Pharmaceuticals Inc |
| Application Number: | US17/064,915 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 10,898,573
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | 10,898,573 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,898,573
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020268329 | ⤷ Start Trial | |||
| Brazil | 112021022404 | ⤷ Start Trial | |||
| Canada | 3139443 | ⤷ Start Trial | |||
| Chile | 2021002918 | ⤷ Start Trial | |||
| China | 111888326 | ⤷ Start Trial | |||
| China | 117045596 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
